以嶺藥業跌超8% 王思聰稱“證監會應嚴查以嶺藥業”
格隆匯4月15日丨昨日漲停的以嶺藥業今日跌超7%。4月14日下午,王思聰轉發一則名為“世衞組織‘推薦’連花清瘟,誰吿訴你的?”的視頻,並發表評論“證監會應嚴查以嶺藥業。現在在中國能看到一個嚴謹、敢於求證、有良心、敢説真話的媒體,實在實在是太難了”。 不過,王思聰很快又刪除了其相關言論。針對王思聰言論,以嶺藥業迴應稱“關於微博上所傳的消息,請指出具體的問題與源頭,我們將對具體內容做解答。不能因為‘王思聰’三個字眼,就隨意提出疑問,投資者請加以甄別”。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.